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Neurodegeneration with brain iron accumulation (NBIA) comprises a clinically and genetically heterogeneous group of disorders with
progressive extrapyramidal signs and neurological deterioration, characterized by iron accumulation in the basal ganglia. Exome
sequencing revealed the presence of recessivemissensemutations in COASY, encoding coenzyme A (CoA) synthase in one NBIA-affected
subject. A second unrelated individual carrying mutations in COASY was identified by Sanger sequence analysis. CoA synthase is a
bifunctional enzyme catalyzing the final steps of CoA biosynthesis by coupling phosphopantetheine with ATP to form dephospho-
CoA and its subsequent phosphorylation to generate CoA. We demonstrate alterations in RNA and protein expression levels of CoA
synthase, as well as CoA amount, in fibroblasts derived from the two clinical cases and in yeast. This is the second inborn error of
coenzyme A biosynthesis to be implicated in NBIA.Introduction
The common pathological feature of a group of genetic
disorders termed ‘‘neurodegeneration with brain iron
accumulation’’ (NBIA) is brain iron overload.1 Distinct
subclasses of early-onset neurodegeneration with auto-
somal-recessive transmission are defined by mutations in
specific genes: PANK2 (MIM 606157) causes pantothenate
kinase-associated neurodegeneration (PKAN);2,3 PLA2G6
(MIM 256600) causes phospholipase A2-associated neuro-
degeneration (PLAN, also known as INAD);4 FA2H (MIM
611026) causes fatty acid hydroxylase-associated neurode-
generation (FAHN);5 and C19orf12 (MIM 614297) causes
mitochondrial membrane protein-associated neurodegen-
eration (MPAN).6,7 More recently, a distinctive form of
NBIA with X-linked dominant de novo mutations in
WDR45 (MIM 300894), coding for a protein with a puta-
tive role in autophagy, was reported.8,9
These genes account for ~70% of subjects with NBIA,
leaving a significant fraction without an identified genetic
defect. For this reason we performed exome sequence
investigation in one individual with clinical presentation
and neuroimaging suggestive of NBIA but without muta-
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The Aapproach we identified a homozygous missense mutation
in COASY, coding for CoA synthase. We then performed
traditional Sanger sequence analysis of a larger cohort of
idiopathic NBIA cases, and we found a second individual
harboring mutations in the same gene. CoA synthase is a
bifunctional enzyme possessing 40PP adenyltransferase
(PPAT) and dephospho-CoA kinase (DPCK) activities, cata-
lyzing the last two steps in the CoA biosynthetic
pathway.10 The enzyme is encoded by a single gene in
mammals and Drosophila,11,12 although two different
genes code for PPAT and DPCK activities in yeast and
bacteria.13 In human there are three splice variants:
COASY alpha is ubiquitously expressed and has a molecu-
lar weight of 60 kDa; COASY beta is predominantly
expressed in the brain and possesses a 29 aa extension at
the N terminus;14 and COASY gamma is predicted to
code for C-terminal region of CoA synthase corresponding
to DPCK domain. Several studies have investigated the
subcellular compartmentalization of the CoA biosynthetic
pathway and have demonstrated that both PANK2, defec-
tive in themost commonNBIA disorder, and CoA synthase
alpha and beta are mitochondrial enzymes. PANK2 is
mainly located in the intermembrane space2,15,16 whereas
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mitochondrial membrane by the N-terminal region17 or
localized within the mitochondrial matrix.18 We here
demonstrate that COASY is mainly located in the mito-
chondrial matrix and that the identified amino acid
substitution causes instability of the protein with altered
function of its enzymatic activity.Subjects and Methods
Exome and Sanger Sequencing
Informed consent for participation in this study was obtained
from all individuals involved and from their parents, in agreement
with the Declaration of Helsinki, approved by the ethics commit-
tee of the Fondazione IRCCS (Istituto di Ricovero e Cura a Carat-
tere Scientifico) Istituto Neurologico C. Besta (Milan, Italy) and
by the ethics committees of the other institutes participating in
the screening (Germany, UK, USA).
Exome sequencing and variant filtering was performed as
described previously.8 In brief, exonic DNA fragments were
enriched with the SureSelect 50 Mb kit from Agilent and
sequenced as 100 bp paired-end reads on a HiSeq 2500 system
from Illumina. For sequencing statistics details see Table S1 avail-
able online. We predicted that causal mutations would be very
rare and would alter the protein. We therefore searched for nonsy-
nonymous variants with a frequency <0.1% in 2,700 control
exomes analyzed in Munich and public databases that, given the
reported consanguinity of the parents, were anticipated to be
homozygous. This analysis left a total of 12 candidate genes (Table
S2). The detailed list of these 12 genes is reported in Table S3. We
first excluded the following genes because of the presence of addi-
tional subjects with compound heterozygous or homozygous
mutations related with different clinical phenotypes: HRNR,
ADAM8, BZRAP1, C17orf47, LRP1B, EVC2, KIAA1797, and
CACNB1. Moreover, variants in HRNR, CACNB1, C17orf47, and
KIAA1797 were predicted to be benign by PolyPhen. Four remain-
ing genes (GUCA2A, FBXO47, COASY, and IFNW1) were poten-
tially good candidates carrying deleterious mutations.
By performing segregation analysis of the c.265G>T homozy-
gous variant in GUCA2A, we found that also the healthy mother
(subject I-2 of family 1) and one of the healthy sisters (subject
II-4 of family 1) carried this variant.
Segregation analysis of c.490A>G in IFNW1 showed that this
change was present in homozygous state in the healthy mother
(subject I-2 of family 1) and in two healthy sisters (subjects II-4
and II-5 in family 1). Altogether, this observation excluded both
GUCA2Aand IFNW1aspotential candidategenes (seealsoTable S3).
FBXO47wasmainly expressed in kidney, liver, and pancreas and
it was suggested to act as a tumor-suppressor gene in renal carci-
noma and possibly other malignancies.19 However, because this
gene carries a splice sitemutation, we decided to perform sequence
analysis in a subgroup of 56 NBIA-affected individuals. We did not
identify any pathogenic mutation in this cohort of subjects.
Based on these data and because COASY coded for an enzyme
involved in Coenzyme A biosynthesis as PANK2, we concentrated
our efforts on the analysis of this gene.RNA Extraction and Real-Time PCR
Total RNAwas isolated from fibroblasts (80% confluence) with the
RNeasy Mini Kit (QIAGEN). RNA quantity was measured with the
Nanodrop instrument (Nanodrop Technologies). RNA was used as12 The American Journal of Human Genetics 94, 11–22, January 2, 20a template to generate complementary DNA (cDNA) by GoScript
Reverse Transcriptase protocol (Promega). Reverse transcriptase
products were used in real-time PCR to evaluate the expression
level of COASY with the Power SYBR Green PCR Master Mix
(Applied Biosystems) system. The housekeeping gene used for
data normalization was GAPDH. Primer sequences are as follows:
COASY, forward 50-AGTTGCGGTTTCTCCGTTAG-30 and reverse
50-ATCCTGGGAGGGGGAAAT-30; GAPDH, forward 50-CTCTG
CTCCTCCTGTTCGAC-30 and reverse 50-ACGACCAAATCCGTT
GA-30.
Expression and Purification of Recombinant hDPCK
in Bacteria
mRNA coding for human DPCK domain (COASY amino acid
sequence from 355 to 564) was expressed with the N-terminal
histidine-tag from pET30-a(þ) (Novagen) at 37C in E. coli strain
BL21 (DE3), after induction with 0.2 mM IPTG.
Cells were lysed by a French press in 50 mM Tris-HCl (pH 8),
0.5MNaCl, 1% Triton X-100, 20mM imidazole, 1 mM phenylme-
thylsulfonyl fluoride (PMSF), 10 mM b-mercaptoethanol, and
Roche Complete EDTA-free protease inhibitor cocktail. After
clearing, the lysate was loaded on a Ni-NTA beads (QIAGEN)
column. Bound proteins were eluted with an imidazole gradient.
Fractions containing His-hDPCK were pooled, desalted, and
loaded onto an anion-exchange (AE) Resource-S column (GE
Healthcare) equilibrated in 50 mM Tris-HCl (pH 7.4), 2.5% glyc-
erol, 20 mM b-mercaptoethanol. The protein was eluted with a
NaCl gradient, concentrated by ultrafiltration, and further sepa-
rated by size exclusion chromatography (SEC) on a Superdex-
200 column (GE Healthcare) equilibrated in 10 mM Tris-HCl
(pH 7.4), 0.15 M NaCl, 2.5% glycerol, 0.1 mM EDTA, and 1 mM
DTT. The entire purification scheme was carried out at 4C.
Mitochondria and Mitoplast Isolation from Cultured
Cells
Isolatedmitochondria from cultured cells were obtained according
to the protocol described by Ferna´ndez-Vizarra.20
For mitoplast purification, mitochondria were dissolved in 1 ml
Buffer A (MOPS 20mM, sucrose 0.25M [pH 7.4]). A total of 1 ml of
200 mg/ml digitonin in Buffer A was added to each sample. Sam-
ples were mixed and incubated on ice 5 min, then centrifuged
3 min at 8,000 rpm at 4C. Supernatant was discarded and pellet
dissolved in 1 ml Buffer B (MOPS 20 mM, sucrose 0.25 M, EDTA
Na4 1 mM [pH 7.4]). Samples were incubated on ice for 5 min,
then centrifuged at 12,000 rpm at 4C for 3min. Separate fractions
of mitochondria and mitoplasts were also treated with 0.04 mg of
proteinase K (PK) for 15 min at 4C or 37C; PK digestion was
blocked with PMSF. In some samples of mitochondria and mito-
plasts, 0.1% Triton X-100 was added followed by incubation for
15 min at 37C.
Immunoblot Analysis
Approximately 1 3 106 fibroblasts, grown in DMEM (EuroClone)
were trypsinized, centrifuged at 1,200 rpm for 3 min, and solubi-
lized in 200 ml of RIPA buffer (50 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 1% NP40, 0.5% NaDOC, 5 mM EDTA) with 13 Complete
Mini Protease Inhibitor Cocktail Tablets (Roche) for 40 min at
4C. 30 mg of proteins were used for each sample in denaturing
sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). Immunoblot analysis was performed as described21 with
the ECL-chemiluminescence kit (Amersham).14
Antibodies
A rabbit monoclonal anti-COASY antibody was used at 1:1,000
dilution (EPR8246-Abcam). Amousemonoclonal anti-b-TUBULIN
antibody was used at a final concentration of 1 mg/ml (Sigma-
Aldrich). Secondary anti-rabbit and anti-mouse antibodies were
used at 1:2,000 and 1:7,000 dilution, respectively.HPLC Analysis of Dephospho-CoA, CoA, and
AcetylCoA
HPLC analysis was performed on recombinant wild-type and
mutant DPCK proteins, on fibroblast lysates derived from control
and subjects carrying COASY variants, and on isolated yeast mito-
chondria.
The method employed a column (Kinetex 5u C18 100A New
Column 250 3 4.6 mm from Phenomenex) eluted with
100 mmol/l NaH2PO4 and 75 mmol/l CH3COONa (pH was
adjusted to 4.6 by the addition of concentrated H3PO4)-acetoni-
trile (94:6, v/v) at a flow rate of 1.0 ml/min. The ultraviolet (UV)
detector was set at 259 nm. To obtain standard solutions of
5 mM, dephospho-CoA and CoA were dissolved in 50 mmol/l
KH2PO4-K2HPO4 buffer (pH 7.0). CoA and dephospho-CoA stan-
dards were eluted at approximately 4.5 and 8 min, respectively,
and CoA compounds were quantified by comparison of peak areas
with those of authentic standards.
In Vitro DPCK Activity
1 mg of purified wild-type or mutant protein was incubated for 2 hr
at 37C in 50 ml of reaction mixture containing 50 mM Tris-HCl
(pH 8), 5 mM MgCl2, 1 mM ATP, and 0.1 mM dephospho-CoA.
After incubation, sample was treated with perchloric acid (PCA)
3%, vortexed, and centrifuged at 13,000 rpm at 4C. Trietanol-
amine was added to the supernatant to a final concentration of
100 mM, and then the sample was neutralized with 5 M K2CO3.
Fibroblast Analysis
Fibroblasts, grown on 10 cm plates (approx. 80%–90% confluent),
were washed with PBS and collected by trypsinization. 40 ml of ice-
cold PCA (5%) was added to cells and samples were vortexed and
centrifuged at 18,000 3 g for 5 min at 4C. The supernatant was
collected and triethanolamine was added to a final concentration
of 100 mM. The pH was adjusted to 6.5 with 5 M K2CO3 before
centrifuging again at 18,0003 g for 3 min at 4C to remove potas-
sium perchlorate. Neutralized PCA extract was made up to 100 ml
with Na2H2PO4 (150 mM), Tris-(2-carboxyethyl) phosphine
hydrochloride (TCEP) (10 mM), EDTA (5 mM), and methanol
(9%) and filtered through a 0.2 mm PVDF filter, and 50 ml was
injected for HPLC analysis of CoA compounds.
In Vitro PPAT/DPCK Assay of Cell Homogenates
Fibroblasts grown on 10 cm plates (approx. 80%–90% confluent)
were washed with PBS and collected by trypsinization. Cells
were homogenized in 150 ml buffer containing 50 mM Tris/HCl
(pH 7.5), 150 mM NaCl, 10 mM 2-glycerophosphate, 1 mM
EDTA, 0.5mMTCEP, and protease inhibitor cocktail (Roche). Total
protein concentration in the homogenate was measured by
Bradford assay. 65 mg of homogenate protein was incubated with
2 mM ATP, 5 mM MgCl2, and 5 mM 4-phosphopantetheine in
a total volume of 50 ml at 30C for 1 hr. 4-phosphopantetheine
was prepared by phosphorylating pantetheine with bacterially
expressed pantothenate kinase 1b. For control incubation, ATP
and MgCl2 were added to homogenate, but 4-phospho-
pantetheine was omitted. After the incubation, PCA (3.5% final)
was added to the reaction mixtures before centrifugation at
18,000 3 g for 5 min at 4C. The pH of the PCA-soluble fractionThe Awas adjusted to 6.5 with TEA/K2CO3 and CoA compounds formed
were analyzed by HPLC as described above.
Yeast Mitochondria Analysis
Mitochondrial suspensions were diluted to obtain about 0.5 mg/ml
in a final volume of 150 ml of 5% 5-sulfosalicylic acid containing
50 mmole/l DTT and vortexed. The homogenates were centrifuged
at 12,000 3 g for 10 min at 4C. The supernatant was passed
through a 0.45 mm filter (Millipore) and the filtrate (40 ml) was
injected directly into the HPLC system. We loaded equal amount
of yeast mitochondrial proteins (40 mg) and we performed CoA
quantification by evaluating peak’s areas as compared to known
concentration of internal standard.
Yeast Strains and Media
Yeast strains used in this study were W303-1B (MATaade2-1 leu2-
3,112 ura3-1 his3-11,15 trp1-1 can1-100) ade2-1 leu2-3,112 ura3-1
trp1-1 his3-11,15, its isogenic strain cab5::KanMx4 that harbors
plasmid pFl38-CAB5 or pFl39-CAB5, and the strain cab5::KanMx4
that harbors plasmid pYEX-BX-COASY (see below). Cells were
cultured in minimal medium 40 supplemented with appropriate
amino acids and bases for auxotrophy as previously described.22
To obtain medium lacking pantothenate (40-Pan), a mixture of
vitamins without pantothenate was prepared. Various carbon
sources (Carlo Erba Reagents) were added at the indicated con-
centration. YP medium contained 1% Bacto-yeast extract and
2% Bacto-peptone (ForMedium). Media were solidified with 20
g/l agar (ForMedium) and strains were incubated at 23C, 30C,
or 37C.
Cloning Procedures and Plasmid Vectors
pFL38-CAB5 was obtained by PCR amplification of CAB5,
including the upstream and the downstream regions, from
genomic DNA of strain W303-1B with primers as follows.
For CAB5 (forward 50-GGGGGGATCCCCATTGCTTAGAA
TGGGCGG-30 and reverse 50-CCGCGGTACCGAGAACCCATA
GAATTCGAC-30), the oligos were modified at 50 end in order to
insert restriction sites for cloning in the centromeric plasmid
pFL38 carrying the URA3 marker.23 pFL39-CAB5 was obtained by
subcloning CAB5 into pFL39 vector carrying the TRP1 marker.23
Human COASY and human COASYArg499Cys were amplified by
PCR from pcDNA3.1 constructs, containing wild-type andmutant
cDNA, respectively, with primers described below.
For COASY (forward 50-GGGGGGATCCATGGCCGTATT
CCGGTCG-30 and reverse 50-CCGCGTCGACTCAGTCGAGGG
CCTGATGAGTC-30), the oligonucleotides contained appropriate
restriction sites to allow cloning in the BamHI-SalI-digested
pYEX plasmid under the control of CUP1 promoter. All cloned
fragments were sequenced to check the absence of mutations. Re-
striction-enzyme digestions, Escherichia coli transformation, and
plasmid extractions were performed with standard methods.24
Site-Directed Mutagenesis and Generation of Yeast
cab5 Strains
The conserved human arginine 499 residue (RefSeq accession
number NM_025233.6), which is replaced by a cysteine in human
COASY, corresponds to arginine 146 (RefSeq NM_001180504.3) in
the yeast protein. The CAB5 mutant allele was obtained by site-
directed mutagenesis (QuikChange II Site-Directed Mutagenesis
Kit Stratagene) by introducing an AGA>TGT codon substitution,
resulting in p.Arg146Cys amino acid change. The corresponding
modified primers used to generate mutated allele are as follows.merican Journal of Human Genetics 94, 11–22, January 2, 2014 13
For COASYArg146Cys (forward 50-CGCAAGAATTGCAACTAGAA
TGTTTAATGACAAGAAATCCTG-30 and reverse 50-CAGGATTTC
TTGTCATTAAACATTCTAGTTGCAATTCTTGCG-30), mutagenized
insert was verified by sequencing of both strands.
The pFL38 plasmid-borne CAB5 was transformed in the W303-
1B by the lithium-acetate method25 to allow cell viability and the
resident CAB5 was deleted with the KanMX4 cassette amplified
from plasmid pCXJKan by primers described below.
For CAB5-Kan (forward 50-CAGATAGCCACAATTAAAATAT
GCTGGTAGTGGGATTGACAGGTCGTACGCTGCAGGTCGAC-30
and reverse 50-GTAATTATAAGATATCAACCTTATACCCGCTGAA
GACTTTTTATTTTGAAGATCGATGAATTGAGCTCG-30), both of
them contained a 50 complementary stretch for an internal
sequence of CAB5 ORF and a 30 complementary stretch (under-
lined in the sequences) for the extremities of the KanMX4 cassette.
Strains with engineered CAB5 were selected on YP supplemented
with 200 mg/ml geneticin and gene rearrangement was confirmed
by PCR. Transformation of cab5::KanR/pFLl38CAB5 strain with
pfl39-CAB5 and pFL39-CAB5Arg146Cys constructs and plasmid
shuffling on media supplemented with 5-FOA in order to select
spontaneous events of Uraþ constructs loss were finally per-
formed. Similarly, cab5::KanR/pFL39CAB5 strain was transformed
with pYEX-BX-COASY and pYEX-BX-COASYArg499Cys constructs;
loss of Trpþ plasmids was induced by growing the transformants
with tryptophan in the medium.
Yeast Mitochondria Isolation
Mitochondria were purified as previously reported.26 In brief, cells
cultured at 28C in the 40 medium supplemented with 0.6%
glucose were collected and washed. Spheroplasts were obtained
after Zymoliase20T digestion (Nacalai Tesque) and disrupted
with a glass-teflon potter homogenizer. Mitochondria were puri-
fied by differential centrifugation. Total protein concentrations
were quantified according to Bradford (Bio-rad).Results
Molecular and Biochemical Investigations
Exome-NGS analysis of one individual (subject II-3, family
1, Figure 1) affected by idiopathic NBIA resulted in the
identification of 12 genes (Table S3) that carried variants
potentially relevant for the disease. However, as described
in detail in the Subjects and Methods section, several of
these genes were not investigated further because (1) the
identified variants were present in additional individuals
and associated with other clinical phenotypes; (2) genetic
segregation analysis was not compatible with clinical pre-
sentation of the subjects of family 1; or (3) gene function
and tissue-specific expression could hardly explain the
neurological presentation. The homozygous mutation in
COASY, coding for a bifunctional enzyme converting 40-
phosphopantetheine into dephospho-CoA and then to
Coenzyme A, was considered as potentially relevant for
the disease and further investigated. By Sanger sequencing
we confirmed the presence of the homozygous missense
COASY mutation in the affected individual (Figure 1: sub-
ject II-3, family 1). The family had no history of neurolog-
ical disorders and this subject was the youngest and the
only affected of five siblings. She was born to consanguin-14 The American Journal of Human Genetics 94, 11–22, January 2, 20eous parents after an uneventful pregnancy and normal
delivery. Birth weight was 3,850 g. There was no history
of perinatal complications and she attained normal early
developmental milestones. From 24 months of age, par-
ents reported gait difficulties and persistent toe walking.
At age 6, when she started primary school, she showed
poor academic ability. At age 15, general physical examina-
tion was normal. Neurological evaluation showed mild
oro-mandibular dystonia with dysarthria and also spastic
dystonic paraparesis, but she was still able to walk unaided.
Neuropsychological evaluation demonstrated cognitive
impairment (total IQ¼ 49). The disease continued to prog-
ress slowly and at the age of 20 she became unable to
ambulate independently. During themost recent examina-
tion at age 25, the clinical picture was dominated by a
severe spastic bradykinetic-rigid syndrome associated
with mild dystonia and with distal areflexia in the lower
limbs. There were no clinical or psychometric data suggest-
ing mental deterioration but behavioral disturbances with
obsessive-compulsive symptoms and depression was
evident. Funduscopic examination and visual evoked
potential studies were normal and on electroretinogram
there were no signs of retinopathy. Electromyographic
and nerve conduction studies were consistent with a
mild motor axonal neuropathy. Serial brain MRI showed
bilateral hypointensity in the globi pallidi associated
with a central region of hyperintensity in the antero-
medial portion (Figure 1).
Identification of one Italian subject carrying COASY
mutation prompted us to analyze the nine exons of this
gene in a cohort of 280 NBIA-affected individuals of
different ethnicity by using polymerase chain reaction
and direct Sanger sequencing. Primer sequences and PCR
conditions are described in Table S4. By this analysis we
identified a second Italian case carrying COASY mutations
(Figure 1: subject II-2, family 2). He is 20 years old and he
was born at term of uneventful pregnancy from healthy
nonconsanguineous parents. Psychomotor development
was normal in the first year of life, but he was delayed in
walking as a result of instability and toe walking. At age 3
the neurological picture was characterized by spastic tetra-
paresis with moderate mental and language impairment.
The disease was progressive, with worsening of the motor
signs in the lower limbs and progressive involvement of
the upper limbs and oro-mandibular region. He lost inde-
pendent ambulation at age 15. At age 17, the neurological
examination showed mild oro-mandibular dystonia with
dysarthria, spastic-dystonic tetraparesis with prevalent
involvement of lower limbs, and parkinsonian features
(rigidity and abnormal postural reflexes). Distal amyo-
trophia and areflexia with pes cavus were also evident.
Cognitive impairment was severe (total IQ < 40) with
obsessive-compulsive behavior and complex motor tics.
On follow-up, 2 years later, the neurological picture was
unchanged. Nerve conduction study and electromyog-
raphy detected a motor axonal neuropathy more promi-
nent in the lower limbs. There was no retinal or optic nerve14
Figure 1. Genetics and MRI of Subjects Carrying COASY Mutations
(A) Pedigrees of family 1 (left) and family 2 (right). II-3, affected individual in family 1; II-2, affected individual in family 2. The presence
of homozygous or compound heterozygous mutation is indicated by /; wild-type sequence by þ/þ; heterozygous mutation by þ/.
(B) Electropherograms show sequence variations in individual II-3 of family 1 (left) and in individual II-2 of family 2 (right).
(C) Left: MRI of individual II-3 of family 1 at 11 years of age (a–c). Axial MR (1.5 T) proton density and T2-weighted images (a, b) show
bilateral low signal intensity in the globi pallidi (clearly visible in b) with a central region of high signal intensity located in the antero-
medial portion of the nuclei (‘‘eye-of-the-tiger’’ sign) and with a large central spot of low signal intensity. Axial CT (c) shows bilateral
hyperdensities consistent with calcifications and corresponding to the central spot visible on MRI. Six years later (d), no changes
were found. The hypointensity in the medial portion of the substantia nigra was also unchanged. Right: MRI of individual II-2 of family
2 at 9 years of age (e, f) and at age 19 (g, h). Axial T2-weighted 1.5 T MR images (e, f) reveal hypointensity in the pallida. Both caudate
nuclei and putamina are swollen and hyperintense. Slight hyperintensity is also present in both medial and posterior thalami (arrows).
Axial T2-weighted MR image (g) confirms bilateral symmetric low signal intensity and atrophy in the pallida. Both putamina and
caudate nuclei are still slightly hyperintense with minimal swelling. Coronal FLAIR image (h) demonstrates low signal in both pallida
and in the medial portion of the substantia nigra (arrowheads).involvement, as demonstrated by normal funduscopic and
evoked potential studies.
The first brain MRI performed at age 5 demonstrated
hyperintensity and swelling of both caudate nuclei and
putamina and mild hyperintensity in both thalami. Globi
pallidi were normal. At ages 9 and 19, hypointensity in the
globi pallidi was evident and no significant changes were
found in the caudate nuclei, putamina, and thalami
(Figure 1).
Subject II-3 of family 1 (Figure 1) carried a homozygous
missense mutation, a c.1495C>T transition causing anThe Aamino acid change p.Arg499Cys (referral sequence
NM_025233.6; numbering starts from the first methio-
nine). Segregation analysis performed in family 1 indicated
heterozygous state in the parents (Figure 1), and the four
healthy sisters showed wild-type sequence (Figure 1).
Subject II-2 of family 2 (Figure 1) turned out to be a com-
pound heterozygote for the same mutation, c.1495C>T
(p.Arg499Cys), identified in subject II-3, and for a
c.175C>T transition, resulting in a premature p.Gln59*
stop codon in the N-terminal regulatory region of the
protein. Segregation analysis in the parents demonstratedmerican Journal of Human Genetics 94, 11–22, January 2, 2014 15
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Figure 2. COASY: Conserved Domains,
Phylogenetic Conservation, and Crystal
Structure
(A) Schematic domain organization of hu-
man CoA synthase and location of point
mutations. Abbreviations are as follows:
MLS, mitochondrial localization signal;
NRD, N terminus regulatory domain;
PPAT, 40PP adenylyltransferase domain;
DPCK, dephospho-CoA kinase domain.
(B) Amino acid sequence alignment
showing conservation of Arg499 across
species.
(C) Crystal structure of E. coliDPCK (CoaE)
(PDB ID 1VHL) showing the position of
Arg140 (equivalent to Arg499 in human
DPCK) in the nucleotide-binding site.that the two mutations were on different alleles: one in-
herited from themother and one from the father (Figure 1).
The healthy brother was not available for genetic testing.
Themissense substitution affected an amino acid residue
Arg499, which is highly conserved in all available animal,
plant, and yeast species, including S. cerevisiae, and is local-
ized in the nucleotide-binding site of the DPCK domain
(Figure 2). Furthermore, mutational analysis of Arg140,
equivalent to Arg499, in the mycobacterial dephospho-
CoA kinase (CoaE) revealed the importance of this residue
in ATP binding and phosphotransfer reaction.27,28
The substitution was predicted to be pathogenic by
in silico analysis according to Polyphen2 (p ¼ 1) and
MutPred (p ¼ 0.909). Frequency of the mutation derived
from the Exome Variant Server and calculated on Euro-
pean, American, and African population was 1 out of
13,005 analyzed cases.
To evaluate the impact of the two mutations on the
stability of the transcript, we extracted mRNA from fibro-
blasts of subjects II-3 (family 1) and II-2 (family 2) and
reverse transcribed it into cDNA. Quantitative real-time
PCR showed that although in individual II-3 the amount
of mutant COASY transcript was similar to that of the
control sample (Figure 3A), it was reduced to 50% in indi-
vidual II-2, suggesting RNA decay.
Next, we analyzed COASY level in total cell lysates
obtained from both mutants and control fibroblasts by
using a monoclonal anti-COASY antibody. We first tested
the antibody specificity by verifying its cross-reactivity
with the 62 kDa COASY alpha in vitro translation product
(Figure 3B).
Immunoblot analysis revealed the presence of a normal
protein content in three different control fibroblasts
whereas a significant reduction of the protein amount
was detected in fibroblasts of subject II-2 (family 2)
carrying the premature stop codon and the missense
p.Arg499Cys (Figure 3B). Interestingly, we also observed a
minimally detectable immunoreactive band correspond-
ing to COASY in subject II-3 (family 1) carrying the homo-
zygous p.Arg499Cys substitution (Figure 3B). This suggests
that the p.Arg499Cys change is associated with instability
or accelerated degradation of the protein. Immunoblot16 The American Journal of Human Genetics 94, 11–22, January 2, 20analysis of fibroblasts derived from subject I-2 of family 1
and from both parents of family 2 (Figure 3B) showed a
partial reduction of the protein level. As reported in
Figure 3C, protein amount quantified by densitometry
analysis with three different controls as standard resulted
to be around 50% in subject I-2 of family 1 and in the
parents of family 2 and less than 5% in both affected indi-
viduals.
Submitochondrial Localization of COASY
To better determine submitochondrial localization of
COASY, we carried out immunoblot analysis of mitochon-
dria and submitochondrial fractions derived from HeLa
cells, using a commercially available antibody (see Subjects
and Methods).
Immunoblotting of different cellular fractions revealed
the presence of a band of the expected molecular weight
in total lysate and intact mitochondria (Figure 4A). To
determine whether the protein was present on the outer
mitochondrial membrane, we treated mitochondria with
proteinase K (PK) and demonstrated COASY resistance to
degradation (Figure 4A). Efficiency of PK activity was
demonstrated by treating mitochondria with Triton
X-100, which dissolves the membranes and makes the
protein accessible to PK digestion (Figure 4A). This result
was further supported by hybridizing the same filter with
control antibodies against proteins such as CORE1 or
ETHE1, which are located in the inner mitochondrial
membrane and in the mitochondrial matrix, respectively,
or against VDAC1, which is located in the outer mitochon-
drial membrane (Figure 4A) facing the intermembrane
space. We observed that COASY was also present in total
lysates and not enriched in the mitochondrial fraction,
suggesting that its localization might not be exclusively
in mitochondria.
The protein was found in mitoplasts and was resistant
to PK digestion. Further fractionation of mitoplasts
demonstrated that the protein was mainly present in the
matrix, probably anchored to the inner mitochondrial
membrane (Figure 4B). The presence of trans-membrane
domains was predicted by TMpred and PSIPRED software.
We also observed the presence of VDAC in mitoplasts,14
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Figure 3. COASY mRNA Expression and
Protein Accumulation in Skin Fibroblasts
(A) Quantification of COASY mRNA levels
by real-time PCR in fibroblasts of subject
II-3 and II-2 relative to the expression of
glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH). The amount of COASY
transcript is reduced in subject II-2 versus
control samples (CT), indicating mRNA
decay. Data are represented as mean 5
SD. Statistically significant differences
with CT were determined by the Student’s
t test; **p < 0.02.
(B) Immunoblot analysis of COASY in
fibroblasts derived from three healthy
subjects (CT 1, CT 2, CT 3), individual I-2
(family 1), individuals I-1 and I-2 (family
2), and affected subjects (II-3 and II-2).
The same amount of protein (30 mg) was
loaded. b-tubulin was used as a loading
control. As a control, COASY in vitro trans-
lation product (COASY peptide) was
loaded.
(C) Relative quantification of the
protein amount: mean 5 SD of three
controls (CT); of individual I-2 (family 1);
of individuals I-1 and I-2 (family 2); and
of affected subjects II-3 and II-2. Histogram
shows COASYamount quantified by densi-
tometry and normalized on b-tubulin
level.suggesting that the outer mitochondrial membrane was
not completely removed. However, VDAC was partially
digested with PK and, most importantly, it was completely
absent in the mitochondrial matrix.
HPLC Assays on Recombinant Protein and Fibroblasts
Derived from Affected Subjects
To assess the effect of the p.Arg499Cys substitution on the
DPCK activity, we expressed mRNA corresponding to the
wild-type and mutant DPCK domain in bacteria as His-
tag fusion proteins. Recombinant proteins were purified
by NTA chromatography and 1 mg of each protein was
loaded on an SDS-PAGE and stained with Coomassie blue
(Figure 5A, top). To demonstrate that the recombinant
proteins were recognized by the anti-COASY antibody,
the gel was blotted and incubated with the specific anti-
body (Figure 5A, bottom). Activities of wild-type DPCK
and of the mutant DPCK-Arg499Cys were measured
in vitro by HPLC analysis via 1 mg of recombinant proteins.
This analysis evaluates dephospho-CoA conversion into
CoA after incubation of wild-type and mutant DPCK
proteins with ATP and dephospho-CoA. As indicated by
the chromatogram in Figure 5B, the wild-type enzyme
was able to completely convert dephospho-CoA into
CoA, as demonstrated by the coincidence of the reaction
mixture peak with that of CoA standard. On the contrary,
the DPCK-Arg499Cys mutant did not have this enzymatic
activity and the peak corresponding to CoA was not
observed (Figure 5C). This finding suggests that CoA
biosynthesis might be abolished in the presence of the
p.Arg499Cys change.The AWe then analyzed CoA levels in fibroblasts derived from
healthy and affected subjects by HPLC, but we did not
observe a significant difference. However, a general reduc-
tion of acetyl-CoA and total CoA was observed in both
affected individuals as compared to control, and this differ-
ence was statistically significant for acetyl-CoA in subject
II-3 of family 1 (Figure 6A).
To examine whether skin fibroblasts from affected
individuals were able to synthesize CoA, we performed
an in vitro assay to evaluate CoA biosynthesis in cell
homogenates with 40PP (40-phosphopantetheine) as
substrate. HPLC analysis of reaction mixtures showed
that dephospho-CoA and CoA were efficiently produced
de novo from 40PP in control fibroblasts (Figure 6B). We
also observed residual de novo production of dephospho-
CoA and CoA in skin fibroblasts from affected subjects,
although the level of CoA was approximately 20% of
that produced by control fibroblasts (Figure 6B). These
findings suggest the existence of an alternative as yet un-
characterized pathway for CoA biosynthesis. However,
we cannot exclude the possibility that the remaining
COASY aberrant protein present in fibroblasts may still
retain some catalytic activity.
Studies in Yeast Saccharomyces cerevisiae
To further test the pathogenic role of the COASY missense
mutation, we used the yeast Saccharomyces cerevisiae.
Biosynthesis of CoA in S. cerevisiae follows the same
pathway described for mammalian cells: pantothenate,
formed de novo from several amino acids or taken up
from outside the cell, is converted in CoA in five reactionsmerican Journal of Human Genetics 94, 11–22, January 2, 2014 17
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Figure 4. Mitochondrial Localization of
COASY
(A) Immunoblot analysis on mitochondria
and different submitochondrial fractions
derived from HeLa cells. Mitochondria
were treated for 15 min at 4C or 37C
with proteinase K (PK) in presence or
absence of triton. The filter was incubated
with anti-COASY, anti-CORE1, anti-
ETHE1, and anti-VDAC1 antibodies. As
a control, COASY in vitro translation
product (COASY peptide) was loaded.
(B) Immunoblot analysis on mitoplasts,
matrix, and inner membrane isolated
from HeLa cells. Mitoplasts were treated
for 15 min at 4C or 37C with PK in pres-
ence or absence of triton. The filter was
sequentially incubated with anti-COASY,
anti-ETHE1, anti-CORE1, and anti-VDAC
antibodies.catalyzed by enzymes encoded by CAB1 through CAB5.29
With the exception of CAB1, the other genes of the
pathway have been identified because of sequence similar-
ity and their function in CoA biosynthesis assessed by
heterologous complementation with bacterial genes. The
only difference with human is that in yeast, as in E. coli,
the PPAT and DPCK activities reside on different proteins
encoded by CAB4 and CAB5 genes, respectively. Deletion
of each CAB gene results in a lethal phenotype, indicating
an essential role for this pathway in yeast.
Sequence analysis indicated that Arg499 is highly
conserved from yeast to human and corresponds to
Arg146 in the yeast Cab5p (see also Figure 2). By using
the plasmid shuffling method, deletion strains express-
ing either the mutant alleles cab5Arg146Cys and
COASYArg499Cys or the CAB5 and COASY wild-type genes
were generated. The Dcab5 lethal phenotype was rescued
by the re-expression of either human COASY wild-type or
human COASYArg499Cys and yeast cab5Arg146Cys. No major
defects of growth on different substrates or at different
temperatures were observed (data not shown).
However, we noticed that the mutant cab5Arg146Cys as
well as the strain expressing COASYArg499Cys became
auxotrophic for pantothenate and showed growth reduc-
tion. In fact, wild-type yeast can form colonies regardless
of the presence of pantothenate at all tested temperatures
(Figure 7A); by contrast, in the absence of pantothenate
both mutants cab5Arg146Cys and COASYArg499Cys failed to
form colonies at 37C and a significant impairment of
growth was observed at both 23C and 28C when
compared with that of the strain expressing the wild-
type alleles (Figure 7B). This result supports the pathoge-
nicity of the substitution p.Arg499Cys and suggests that
the mutant enzyme requires a higher concentration of
pantothenate to produce enough CoA to sustain yeast
growth.
Because Cab5p as COASY is located into the mitochon-
dria,30 we measured the level of CoA in mitochondria
isolated from wild-type, COASYArg499Cys, and cab5Arg146Cys18 The American Journal of Human Genetics 94, 11–22, January 2, 20transformed yeasts grown in complete medium at 28C
with 0.6% glucose. We first verified, by immunoblot
analysis, that COASYArg499Cys was expressed in yeast at a
comparable level as in the wild-type enzyme (not shown).
We could not verify cab5Arg146Cys expression because the
available antibody did not cross-react with the yeast
protein. We observed that the level of CoA was reduced
to 40% in yeast transformed with both the human
COASYArg499Cys and yeast cab5Arg146Cys mutant versions
as compared to wild-type (Figure 8).Discussion
We here report the second inborn error of CoA synthesis
leading to a neurodegenerative disorder. The first defect
discovered was due to PANK2 mutations, causing the
most prevalent NBIA subtype, PKAN.2
Coenzyme A (CoA) is a crucial cofactor in all living
organisms and is involved in several enzymatic reactions.
It is a key molecule for the metabolism of fatty acids,
carbohydrates, amino acids, and ketone bodies. Its biosyn-
thesis proceeds through a pathway conserved from
prokaryotes to eukaryotes, involving five enzymatic steps,
which utilize pantothenate (vitamin B5), ATP, and
cysteine.
In the first step, catalyzed by pantothenate kinase,
the product of PANK2, pantothenic acid is phosphorylated
to generate 40-phosphopantothenic acid. Then, this inter-
mediate is converted into 40-phosphopantothenoyl-
cysteine, which is subsequently decarboxylated to
40-phosphopantetheine. The last two steps are carried
out by the bifunctional enzyme CoA synthase, which
converts 40-phosphopantetheine into dephospho-CoA
and then CoA.31
We have identified mutations in the COASY in two
subjects with clinical and MRI features typical of NBIA.
They displayed a strikingly similar phenotype, more severe
in subject II-2 of family 2, presenting with early-onset14
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Figure 5. HPLC Analysis of CoA Produc-
tion by Wild-Type and Mutant DPCK
Recombinant Proteins
(A) Top: equal amount of purified wild-
type and mutant DPCK proteins were
loaded on a 12% SDS page and stained
with Coomassie blue. Bottom: immuno-
blot analysis on the same gel showing
that anti-COASY antibody is able to recog-
nize both the wild-type and the mutant
protein.
(B) Chromatogram showing the peak cor-
responding to the reaction product (green)
obtained from incubation of wild-type
DPCK recombinant protein with ATP and
dephospho-CoA.
(C) Chromatogram showing the peak cor-
responding to the reaction product (green)
obtained from incubation of mutant
DPCK-Arg499Cys recombinant protein
with ATP and dephospho-CoA. Red peak,
CoA standard; blue peak, dephospho-CoA
standard.spastic-dystonic paraparesis with a later appearance of
parkinsonian features, cognitive impairment, and pro-
nounced obsessive-compulsive disorder. The disease was
slowly progressive with loss of ambulation during adoles-
cence and adulthood. This phenotype overlaps with other
NBIA disorders, including the presence of an axonal
neuropathy, which is commonly reported in phospholi-
pase A2-associated neurodegeneration (PLAN) and also in
mitochondrial membrane protein-associated neurodegen-
eration (MPAN) cases.32
In subject II-3 of family 1, MR images are reminiscent of
the ‘‘eye-of-the-tiger’’ sign even if with subtle features,
which differentiate it from the typical appearance present
in PKAN.33,34 In subject II-2 of family 2, an isolated
involvement of neostriatum, which usually hallmarks a
metabolic rather than degenerative disorder, preceded
the evidence of the typical increase of pallida iron content.
Such features have not been previously reported, expand-
ing the MR spectrum of NBIA disorders.0 
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statistically significant. A reduction of total CoA was observed in bo
(B) De novo synthesis of CoA and dephosphoCoA (dpCoA) in primar
two affected individuals (II-3, family 1; II-2, family 2). CoA (white bar
tified by HPLC after deproteinization of reaction mixture with PCA
independent experiments. Statistically significant differences with C
The ABoth individuals presented with a severe neurological
disorder but they have survived up to the third decade
of life, suggesting the presence of residual amount of
CoA as observed in cultured fibroblasts. The complete
absence of CoA would be probably incompatible with
life, and organisms have developed alternative strategies
to counteract deleterious effects of mutations in CoA
enzymatic pathway. For instance, mammals possess four
closely related PANK isoforms,2 1a, 1b, 2, and 3, which
exhibit a tissue-specific pattern of expression. This redun-
dancy could explain why PKAN patients can survive into
the first or second decade of life. Probably, the different
isoforms can compensate each other to maintain
adequate CoA level. This was clearly demonstrated in
mice by the simultaneous knockout of two different
Pank genes.35
COASY has been reported to code for three transcript
variants resulting in tissue-specific isoforms.14 The exis-
tence and functional significance of these variants are* 
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Figure 6. HPLC Analysis of CoA and CoA
Derivatives in Fibroblasts
(A) CoA (white bar), acetyl-CoA (black bar),
and total CoA (gray bar) levels in primary
skin fibroblasts derived from a healthy
control (CT) and from the two affected
individuals (II-3, family 1; II-2, family 2).
Results shown are mean 5 SEM of four
independent experiments. Statistically
significant differences in acetyl-CoA
amount between CT and subject II-3 (fam-
ily 1) were determined by the Student’s
t test; *p < 0.05. This subject also shows
a reduction in acetyl-CoA, which is not
th affected individuals, although not statistically significant.
y skin fibroblasts derived from a healthy control (CT) and from the
) and dpCoA (gray bar) produced from 40PP as substrate were quan-
(3% final). Results shown are mean 5 SEM of values from three
T were determined by the Student’s t test; **p < 0.02.
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Figure 7. Growth of Yeast Strains in Presence or Absence of
Pantothenate
The strain Dcab5 was transformed with pFL39 plasmid carrying
the wild-type CAB5 and the mutant allele cab5Arg146Cys (A) or
with pYEX-BX plasmid carrying COASY and COASYArg499Cys (B).
Equal amounts of serial dilutions of cells from exponentially
grown cultures (105, 104, 103, 102, 101 cells) were spotted onto
minimum medium 40 plus 2% glucose, with or without panto-
thenate 1 mg l1. The growth was scored after 3 days of incuba-
tion at 23C, 28C, or 37C. Each experiment of serial dilution
grow test was done in triplicate starting from independent yeast
cultures.
Figure 8. HPLC Analysis of CoA in Yeast Mitochondria
CoA level in mitochondria isolated from Dcab5 yeast transformed
with wild-type (WT) or mutant (p.Arg146Cys) yeast CAB5 (A), and
with wild-type or mutant (p.Arg499Cys) human COASY (B). Equal
amount of mitochondrial proteins (40 mg) were used in each assay.
Results shown are mean 5 SD of values from three independent
experiments. Values of mutant samples are expressed as percent-
age of values obtained in wild-type samples taken as 100%. Statis-
tically significant differences were determined by the Student’s
t test; *p < 0.05; **p < 0.02.presently unknown but both mutations found in this
study affect the protein sequence common to isoforms
alpha and beta, predicting overall impairment of COASY
function. Considering the ubiquitous presence of the
enzymatic COASY activity, it remains unexplained why
only the brain is affected and other organs are preserved.
It is possible that a more severe impairment of CoA levels
occurs in this organ, thus explaining the prevalence of
neurological symptoms. At the cellular level CoA
concentration is regulated by numerous factors, including
hormones, glucocorticoids, nutrients, and cellular metabo-
lites,36,37 and a link between the complex signaling mTOR
pathway, which is implicated in numerous metabolic and
signaling processes, and CoA biosynthesis has been pro-
posed.38 Moreover, it is relevant to notice that the muta-
tions targeted genes coding for pantothenate kinase39
and PPAT activity of CoA synthase36 are the two rate-
limiting steps in CoA biosynthesis. All together these fac-
tors could contribute to modulate the clinical presentation
of individuals carrying COASY mutations.
It is still unknown how mutations in genes involved in
Coenzyme A enzymatic pathway cause neurodegeneration20 The American Journal of Human Genetics 94, 11–22, January 2, 20with iron accumulation in specific areas of the brain but
whereas for PANK2 it was hypothesized that cysteine accu-
mulation may chelate iron and catalyze free radical forma-
tion,40 a different mechanism could be involved in case of
COASY mutations.
In Drosophila it has been demonstrated that abolishing
the different genes of CoA biosynthetic pathway including
the fumble/PANK2 and PPAT-DPCK activities causes a
neurological phenotype characterized by brain vacuoliza-
tion without iron accumulation.12
Identification of mutations in CoA synthase strongly
reinforces the essential role of CoA biosynthetic pathway
for the development and functioning of the nervous
system. This also underlines the importance of further
investigations on different subcellular pools of CoA avail-
able, because a specific mitochondrial pathway could exist
considering that both PANK2 and CoA synthase are mito-
chondrial enzymes.16–18 At present it is not understood
whether CoA can pass from cytosol to mitochondria,
even if a CoA-specific carrier has been identified in the
inner mitochondrial membrane.41 Moreover, it is not clear
whether the regulation of the different pools is coordi-
nated and whether the utilization could be modulated in
response to different physiological or pathological condi-
tions.
In conclusion, we have demonstrated that COASY
mutations cause a distinctive NBIA subtype. This finding
will require further investigation to understand the
connection linking CoA metabolism to neurodegenera-
tion, iron accumulation, and mitochondrial bioenergetics.
We propose CoPAN, standing for COASY protein-associ-
ated neurodegeneration, as the acronym for NBIA caused
by CoA synthase mutations to conform with the current
nomenclature in use to classify these disorders.14
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